Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising ...

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking ...

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

A nasty dip for Hims HIMS Monday. Novo Nordisk confirmed that they are terminating their collaboration with the company due to concerns about their “illegal mass compounding and deceptive marketing.” ...

Wegovy, to be in pharmacies by the end of June, has been launched in a pen-injection format with strengths ranging from 0.25 ...

AstraZeneca (NASDAQ:AZN) on Monday night received accelerated approval from the U.S. Food and Drug Administration (FDA) for its lung cancer drug Datroway.

While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...

The UK’s medicines regulator has received over 100 reports of deaths potentially associated with widely used weight loss ...

Enterprise Ireland’s Food Innovation Summit returns to Croke Park, uniting pioneers, startups and global leaders to explore ...

Most of us have spent a significant amount of time trying to shed off those extra kilos that have left 23 per cent of Kenyan ...